arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CURIS INC

CRIS
$0.85 ▼ -0.16 (-15.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

CURIS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.2M
Dividend Yield —
Revenue Growth -13.4% ↘
Op. Margin -60.5% ↗
ROIC -82.6% ↘
FCF / Share $-2.07 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.44M
↓ -13.4% —
Net Income Profit after all expenses
$-7.58M
↑ +82.5% —
Operating Margin Operating profit as % of sales
-60.5%
↑ +85.2% 4th
FCF / Share Free cash flow per share
$-2.07
↑ +67.1% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↓
6
Financial Health ↑
39
Cash Quality ↑
93

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters